Image pharmaphorum Editor Oncology Realising the promise of genomic testing across oncology Unlocking the secrets of the human genome has long been an ambitious pursuit for researchers around the world. Oncology Diversity by design: the importance of DE&I in oncology tria... “First, do no harm”; is an ethical axiom at the heart of medical research; physicians worldwide pledge to uphold the oath to serve patients. Oncology Immunotherapy: building the fourth pillar of cancer treatmen... Cancer treatment has been traditionally characterised by surgery, chemotherapy, and radiation. Views & Analysis Digital tools driving innovative clinical trials The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the cl Load more results
Oncology Realising the promise of genomic testing across oncology Unlocking the secrets of the human genome has long been an ambitious pursuit for researchers around the world.
Oncology Diversity by design: the importance of DE&I in oncology tria... “First, do no harm”; is an ethical axiom at the heart of medical research; physicians worldwide pledge to uphold the oath to serve patients.
Oncology Immunotherapy: building the fourth pillar of cancer treatmen... Cancer treatment has been traditionally characterised by surgery, chemotherapy, and radiation.
Views & Analysis Digital tools driving innovative clinical trials The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the cl
Oncology On looking to a future multiomics approach for CDx, with Jan... The pharmaphorum podcast caught up with Jane Li, VP and general manager for companion diagnostics at Thermo Fisher Scientific, following ESMO 2026.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.